Aina Mesquida,Eva Alcoceba,Eduardo Padilla,Aída Ramírez,Paloma Merino,Fernando González‐Romo,Elena De Carolis,Maurizio Sanguinetti,María de los Ángeles Mantecón‐Vallejo,María Muñoz‐Algarra,Teresa Durán‐Valle,Ana Pérez‐Ayala,Elia Gómez‐García‐de‐la‐Pedrosa,María del Carmen Martínez‐Jiménez,Miguel Ángel Sánchez‐Castellano,Inmaculada Quiles‐Melero,María Soledad Cuétara,Aída Sánchez‐García,Patricia Muñoz,Pilar Escribano,Jesús Guinea,the CANDIMAD study group,Elena De Carolis,María del Carmen Martínez‐Jiménez

Abstract:Background Fluconazole‐resistant Candida parapsilosis is a matter of concern. Objectives To describe fluconazole‐resistant C. parapsilosis genotypes circulating across hospitals in Spain and Rome and to study their azole‐resistance profile associated with ERG11p substitutions. Patients/Methods We selected fluconazole‐resistant C. parapsilosis isolates (n = 528 from 2019 to 2023; MIC ≥8 mg/L according to EUCAST) from patients admitted to 13 hospitals located in five Spanish cities and Rome. Additionally, we tested voriconazole, posaconazole, isavuconazole, amphotericin B, micafungin, anidulafungin and ibrexafungerp susceptibility. Results Of the 53 genotypes found, 49 harboured the Y132F substitution, five of which were dominating city‐specific genotypes involving almost half the isolates. Another genotype involved isolates harbouring the G458S substitution. Finally, we found two genotypes with the wild‐type ERG11 gene sequence and one with the R398I substitution. All isolates were fully susceptible/wild‐type to amphotericin B, anidulafungin, micafungin and ibrexafungerp. The azole‐resistance patterns found were: voriconazole‐resistant (74.1%) or voriconazole‐intermediate (25.2%), posaconazole‐resistant (10%) and isavuconazole non‐wild‐type (47.5%). Fluconazole‐resistant and voriconazole non‐wild‐type isolates were likely to harbour substitution Y132F if posaconazole was wild type; however, if posaconazole was non‐wild type, substitution G458S was indicated if isavuconazole MIC was >0.125 mg/L or substitution Y132F if isavuconazole MIC was ≤0.125 mg/L. Conclusions We detected a recent clonal spread of fluconazole‐resistant C. parapsilosis across some cities in Spain, mostly driven by dominating city‐specific genotypes, which involved a large number of isolates harbouring the Y132F ERG11p substitution. Isolates harbouring substitution Y132F can be suspected because they are non‐susceptible to voriconazole and rarely posaconazole‐resistant.

Fluconazole‐resistant Candida parapsilosis genotypes from hospitals located in five Spanish cities and one in Italy: Description of azole‐resistance profiles associated with the Y132F ERG11p substitution